Wernstedt P, Brune M, Andersson P-O, Gustavsson B, Stockelberg D, Wadenvik H
Hematology Section, Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden.
Bone Marrow Transplant. 2002 Dec;30(12):971-3. doi: 10.1038/sj.bmt.1703760.
We present a patient with a Philadelphia chromosome positive (Ph+) acute lymphocytic leukaemia (ALL) refractory to standard induction chemotherapy. Treatment with the ABL-specific tyrosine kinase inhibitor STI571 (Glivec, Gleevec, imatinib mesylate) resulted in a complete haematologic and cytogenetic remission. Allogeneic stem cell transplantation from an unrelated donor could be undertaken while the patient was in STI571-induced complete remission from the leukaemia. At present, the patient has a 15-month post-transplantation follow-up and is in stable molecular remission as evaluated by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for the BCR/ABL fusion gene transcript. Our case demonstrates that STI571 can act as a bridge to potentially curative allogeneic stem cell transplant in otherwise poor prognosis Ph+ ALL.
我们报告了一名费城染色体阳性（Ph+）的急性淋巴细胞白血病（ALL）患者，该患者对标准诱导化疗耐药。使用ABL特异性酪氨酸激酶抑制剂STI571（格列卫，甲磺酸伊马替尼）治疗后，患者实现了完全血液学缓解和细胞遗传学缓解。在患者因STI571诱导白血病完全缓解期间，可进行来自无关供体的异基因干细胞移植。目前，患者移植后已随访15个月，通过定量逆转录聚合酶链反应（qRT-PCR）检测BCR/ABL融合基因转录本，处于稳定的分子学缓解状态。我们的病例表明，STI571可作为预后不良的Ph+ ALL患者接受潜在治愈性异基因干细胞移植的桥梁。
